<DOC>
	<DOCNO>NCT00799903</DOCNO>
	<brief_summary>This study test whether darapladib safely low chance cardiovascular event ( heart attack stroke ) people coronary heart disease .</brief_summary>
	<brief_title>The Stabilization Atherosclerotic Plaque Initiation Darapladib Therapy Trial</brief_title>
	<detailed_description>Subjects qualify study randomized 1:1 either darapladib placebo administer addition standard therapy . Following baseline visit , subject expect return clinic visit 1 month , 3 month , every 6 month end study . Average time study individual subject expect 3 year .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<criteria>Men woman least 18 year old . Women must postmenopausal use highly effective method avoidance pregnancy . Current treatment statin therapy unless study doctor determine statin appropriate subject . Chronic coronary heart disease At least one following : At least 60 year old Diabetes require treatment medication Low HDL cholesterol ( `` good cholesterol '' ) Currently smoke cigarette stop smoke within past 3 month Diagnosed mild moderate reduction kidney function Cerebrovascular disease ( carotid artery disease ischemic stroke 3 month prior study entry ) OR peripheral arterial disease . Planned coronary revascularization ( stent placement heart bypass ) major surgical procedure . Liver disease Severe reduction kidney function OR removal kidney OR kidney transplant Severe heart failure Blood pressure high normal despite lifestyle change treatment medication Any lifethreatening disease expect result death within next 2 year ( heart disease ) Severe asthma poorly control medication Pregnant ( Note : A pregnancy test perform nonsterile woman prior study entry ) Previous severe allergic response food , drink , insect sting , etc . Drug alcohol abuse within past 6 month OR mental/psychological impairment may prevent subject comply study procedure understand goal potential risk participate study . Certain medication may interfere study medication ( identify study doctor ) Participation study investigational medication within past 30 day Current participation study investigational device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>heart disease</keyword>
	<keyword>Lp-PLA2 inhibitor</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>CV risk</keyword>
	<keyword>Atherosclerosis</keyword>
</DOC>